Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies - The Lancet
$ 7.50
In stock
Product Description
Full article: Emerging oral drug options for ulcerative colitis
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
Open Access Articles - The Lancet - Journal - Elsevier
Diet and ulcerative colitis.
Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double- blind, placebo-controlled phase 2 study - The Lancet
Out-patient Treatment of Ulcerative Colitis
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial - The Lancet
Biomedicines, Free Full-Text
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study - Gastroenterology
AB1831-HPR SYSTEMATIC REVIEW OF LABORATORY MONITORING GUIDELINES OF CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
IJMS, Free Full-Text
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis - Gastroenterology
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
:format(jpeg)/cdn.vox-cdn.com/uploads/chorus_image/image/56273275/91984025.0.jpg)
